Adherence to Aromatase Inhibitors: The Role of Partners
This trial is active, not recruiting.
|Condition||breast cancer survivors|
|Sponsor||Abramson Cancer Center of the University of Pennsylvania|
|Start date||July 2014|
|End date||April 2016|
|Trial size||40 participants|
|Trial identifier||NCT02753985, UPCC 15114|
This is a qualitative study which explores the role that partners play in breast cancer survivors adherence to aromatase inhibitors and management of their side effects. Both patients and their partners will be interviewed (separately) in order to capture multiple perspectives. The target number of subjects is 64 (32 patients and 32 partners). The primary method of data collection will be face-to-face semi-structured interviews. These interviews will be audio-recorded.
Number of Surveys Completed
time frame: 2 years
Female participants at least 18 years old.
- Women and partners of women with stage I-III breast cancer who
- have completed primary cancer treatments (surgery, chemotherapy, radiotherapy)
- have experienced AI side effects
- live with a romantic partner.
|Official title||Adherence to Aromatase Inhibitors: The Role of Partners|
|Principal investigator||Jun Mao, MD|
Call for more information